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S U M M A R Y
Objective: To characterize the epidemiology and transmitted drug resistance mutation (TDRM) patterns
among individuals with newly diagnosed HIV-1 infection seen at Henry Ford Hospital in Detroit from
2006 to 2008.
Methods: This was a retrospective analysis of medical records from individuals aged 18 years with a
new diagnosis of HIV-1 infection. Individuals who underwent genotypic resistance testing were included
in the study.
Results: One hundred thirty-three individuals were included; 99 (74%) were males, 104 (78%) were
African-Americans, and 61 (46%) had a CD4+ count of 200 cells/ml. The prevalence of TDRM was 17%
(23/133). Non-nucleoside reverse transcriptase mutations occurred in 11 (8%), nucleoside reverse
transcriptase mutations in 13 (10%), and protease inhibitor mutations in 10 (8%). CD4+ count >350 cells/
ml and HIV viral load on presentation were associated with TDRM in the multivariate analysis (p = 0.004
and p < 0.001 respectively).
Conclusions: Late diagnosis of HIV-1 and transmitted antiretroviral resistance are relatively common in
Detroit. While most newly diagnosed persons were candidates for antiretroviral therapy on
presentation, the high prevalence of TDRM has signiﬁcant implications in the selection of ﬁrst-line
highly active antiretroviral therapy (HAART).
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The January 2011 HIV treatment guidelines from the US
Department of Health and Human Services (DHHS) recommend an
earlier initiation of antiretroviral therapy (ART).1 However, a
substantial proportion of individuals ﬁrst access care with
relatively advanced immunodeﬁciency.2 In industrialized nations,
more than a third of HIV-infected persons present with a CD4+ cell
count below 200 cells/ml.3 In Detroit, 41.3% of persons newly
diagnosed with HIV from 2006 to 2008 had AIDS at the time of HIV
diagnosis.4 In fact, based on the DHHS guidelines, 50% of
individuals in Michigan may be candidates for initiation of ART
2 years after estimated HIV seroconversion.5
These same guidelines also recommend several antiretroviral
regimens as preferred options in the initial treatment of HIV
infection.6 In the USA, the prevalence of mutations associated with
reverse transcriptase and protease inhibitor resistance among new* Corresponding author. Tel.: +1 313 318 8270; fax: +1 313 916 4466.
E-mail addresses: mhuamanjoo@gmail.com, mhuaman1@hfhs.org
(M.A. Huaman).
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doi:10.1016/j.ijid.2011.06.007HIV-1 diagnoses was estimated at 14.6% based on multicenter
surveillance data from 2006.7 Hence susceptibility testing is
recommended prior to initiation of ART in all HIV-infected
individuals.6,8 Moreover, continued analysis of drug resistance
surveillance data helps determine the appropriateness of ﬁrst-line
regimens.9
In 2001, the frequency of transmitted drug resistance mutations
(TDRM) in the Detroit area was estimated at 8.7%.10 In order to
determine current TDRM patterns and also to characterize local
epidemiology of the HIV epidemic, a retrospective study was
undertaken among those with a newly diagnosed HIV infection
seen at Henry Ford Hospital (HFH) in Detroit from 2006 to 2008.
2. Methods
Newly diagnosed HIV-1-infected individuals aged 18 years,
who had a ﬁrst HIV genotype done between January 2006 and
December 2008 and entered care for the ﬁrst time at Henry Ford
Hospital (HFH), were included in this retrospective study. HFH is a
non-proﬁt 850-bed tertiary care hospital located in Detroit
downtown and has a referral base that includes the Detroit
metropolitan area and southeastern Michigan. Individuals wereses. Published by Elsevier Ltd. All rights reserved.
Table 1
Characteristics of individuals with newly diagnosed HIV-1 infection
Population characteristics Number of individuals,
n (%) (N = 133)
Male 99 (74.4)
Age, years
Mean  SD 36.8  12
Median (IQR) 36 (26–46)
Race
African-American 104 (78.2)
Caucasian 22 (16.5)
Hispanic/Asian/other 7 (5.3)
HIV risk behaviora
Male to male sex 61 (45.9)
Heterosexual contact 68 (51.1)
Intravenous drug use 4 (3.0)
Setting of diagnosis
HFH outpatient clinic 71 (53.4)
Inpatient 38 (28.6)
Emergency department 13 (9.7)
Other outpatient facility 11 (8.3)
CD4+ count
Mean  SD, cells/ml 277  266
Median (IQR), cells/ml 220 (38–422)
50 38 (28.6)
51–200 23 (17.3)
201–350 28 (21.1)
351–500 18 (13.5)
>500 26 (19.5)
Viral load
Mean  SD, log10 copies/ml 4.68  0.76
Median (IQR), log10 copies/ml 4.73 (4.28–5.26)
2.3–3.0 5 (3.8)
3.0–5.0 81 (60.9)
>5.0 47 (35.3)
Type of insurance
Private 71 (53.4)
Medicare/Medicaid 17 (12.8)
No insurance 45 (33.8)
SD, standard deviation; IQR, interquartile range; HFH, Henry Ford Hospital.
a Patient self-report of HIV risk behavior.
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infection was self-reported and there was no prior history of HIV
infection in HFH medical records.
Demographic, clinical, and laboratory information were col-
lected from the HFH electronic medical record system. Data
collection included HIV transmission categories, setting of
diagnosis, AIDS deﬁning illness, and initial CD4+ cell count and
HIV viral load. Opportunistic infections associated with HIV/AIDS
were based on US Centers for Disease Control and Prevention (CDC)
criteria.11 Late diagnosis of HIV-1 infection was deﬁned as having a
CD4+ count <200 cells/ml at the time of diagnosis.
Genotypic antiretroviral resistance testing was performed on
the reverse transcriptase (RT) and protease (PR) regions of viral
RNA extracted from initial pre-therapy specimens using the
Trugene HIV-1 Genotype assay (Siemens Healthcare Diagnostics,
Deerﬁeld, IL, USA). Resistance was deﬁned as the presence of at
least one major resistance mutation in any drug class, according to
surveillance-deﬁned transmitted HIV-1 drug-resistance muta-
tions.12 HIV subtype was determined by the Stanford University
HIVdb Genotypic Resistance Interpretation Program.13 HIV sur-
veillance drug resistance mutations were identiﬁed by the
Stanford University Calibrated Population Resistance (CPR) Tool
version 5.0 beta utilizing the 2009 drug resistance mutations
(DRM) list.14
Phylogenetic analysis was conducted using BioNumerics 3.5
software (Applied Maths BVBA, Austin, TX, USA). Sequences
obtained by direct sequencing were analyzed using the sequence
from HXB-2 (accession number K03455) as a comparator for
alignment. Trees were constructed using the neighbor-joining (K-
2-P) model with 100 bootstrap replicates and the method of
maximum parsimony.
Data were analyzed using Stata v10.0 (StataCorp LP, College
Station, TX, USA) and described using central tendency measures
with conﬁdence intervals set at 95% (95% CI). The Chi-square test
was used for the analysis of categorical variables; Mann–Whitney
and t tests were used for numeric variables. Simple and multiple
logistic regression models were used to determine the factors
associated with resistance mutations. Results from logistic regres-
sions are reported as the odds ratio (OR). Variables included in the
logistic regression analysis were as follow: sex, age (in quartiles),
ethnicity (African-American vs. Caucasian vs. others), transmission
risk (men who have sex with men vs. heterosexual vs. intravenous
drug user), year of HIV diagnosis, CD4+ count (as a continuous
variable, then transformed into categories <200, 200–350, >350
cells/ml), and viral load (as a continuous variable, log10-trans-
formed). The number of variables included in the ﬁnal multiple
logistic regression model was determined based on the total number
of mutations. Variables were selected following the maximum
likelihood approach. p-Values of <0.05 were considered signiﬁcant.
This study was approved by the HFH Institutional Review
Board.
3. Results
Of 501 ﬁrst time patients who presented between 2006 and
2008, 137 were found to have a new diagnosis of HIV-1 and met the
inclusion criteria for the study. Four individuals were excluded, as
genotype data ﬁles could not be rescued for Stanford HIV drug
resistance analysis. Of the 133 individuals included in the ﬁnal
analysis, all had RT and PR sequences with homology to HIV-1
clade B, as determined by the Stanford HIVdb algorithm. Their
mean age was 36.8 years; 99 (74%) were male and 104 (78%) were
African-American (Table 1). Seventy-one individuals were ﬁrst
diagnosed with HIV-1 infection in the outpatient setting (53%),
while 38 (29%) cases were detected during hospitalization. In
terms of risks behaviors associated with HIV transmission, 61(46%) were men who have sex with men (MSM); however, 68
individuals (85% of women and 39% of men) were self-identiﬁed as
heterosexual. Only four (3%) patients reported intravenous drug
use.
At the time of HIV diagnosis, 38 (29%) individuals were
asymptomatic, and HIV was detected via routine screening. The
other 95 (71%) patients were symptomatic and sought medical
care for a variety of reasons. Fifty-three (56%) of the 95
symptomatic patients had an opportunistic infection. The mean
CD4+ cell count at the time of HIV diagnosis was 277 cells/ml; 46%
had less than 200 cells/ml, and only 20% had counts above 500
cells/ml. The mean plasma HIV RNA was 4.68 log10 copies/ml, and
viral load was above 5 log10 copies/ml in 35%. A total of 68
individuals (51%) had AIDS at the time of HIV diagnosis.
Overall, 23 (17%) of the 133 individuals had at least one
mutation associated with transmitted resistance to reverse
transcriptase or protease inhibitors (Table 2). Non-nucleoside
reverse transcriptase inhibitor (NNRTI) mutations occurred in 11
individuals (8%). Resistance mutations for nucleoside reverse
transcriptase inhibitors (NRTI) were present in 13 (10%). Protease
inhibitor (PI) resistance mutations were found in 10 (8%). Single
class resistance mutations were present in 15 (11%), two class
mutations in six (5%), and three class mutations in two (2%) of the
study population. The most common NRTI mutation was T215D/E/
S (5%). The most common NNRTI mutation was K103N (8%),
whereas L90 M was the most frequent PI mutation (5%). Among
those with two class mutations (n = 6), all of them had NRTI and
NNRTI mutations. The most common NRTI mutation in this group
was M184 V in three (50%), whereas the most frequent NNRTI
Table 2
Frequency of resistance mutations in the reverse transcriptase and protease genes
(N = 133)
Drug class Mutation site Frequency %
NRTI 13 9.8
NNRTI 11 8.3
PI 10 7.5
One class 15 11.3
Two classes 6 4.5
Three classes 2 1.5
NRTI T215D/E/S 6 4.5
M41L 3 2.3
M184I/V 4 3
L210W 2 1.5
K219N/Q 3 2.3
D67N 1 0.8
L74V 1 0.8
NNRTI K103N 10 7.5
Y181C 3 2.3
G190A 1 0.8
Y188L 1 0.8
PI L90M 6 4.5
I54V 1 0.8
I85V 1 0.8
D30N 1 0.8
V82A 1 0.8
NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor.
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mutations (n = 2), mutations were as follows: D67N, T215S, K219Q,
K103N, I54 V, V82A in one person, and T215S, K103N, I85 V in
another.
In the bivariate analysis, no signiﬁcant associations were found
between antiretroviral resistance mutations and age, sex, race,
transmission risk, site of diagnosis, year of diagnosis, or
comorbidities. A higher frequency of resistance mutations was
associated with a CD4+ cell count >350 cells/ml (OR 6.5, 95% CI
1.9–21.6; p < 0.001; Table 3). Among those individuals with a
CD4+ count >350 cells/ml and at least one resistance mutation
(n = 14), ﬁve (36%) had K103N, ﬁve (36%) had L90 M, four (29%) had
T215E/N/S, three (21%) had Y181C, two (14%) had M41L, two (14%)Table 3
Factors associated to antiretroviral resistance mutations by simple and multiple logist
Factor Categories Resistance mutations, n (%) 
Sex Female 5 (14.7) 
Male 18 (18.2) 
Age (quartiles) 18–25 years 7 (21.9) 
26–36 years 7 (18.4) 
37–45 years 4 (13.8) 
46–65 years 5 (14.7) 
Race Caucasian 4 (18.2) 
AA 18 (17.3) 
Other 1 (14.3) 
Transmission risk Heterosexual 8 (11.8) 
MSM 14 (22.9) 
IVDU 1 (25) 
Year of HIV diagnosis 2006 8 (17) 
2007 6 (16.7) 
2008 9 (18) 
CD4+ count (cells/ml) <200 4 (6.7) 
200–350 5 (17.2) 
>350 14 (31.8) 
Viral load Log10
c
OR, odds ratio; CI, conﬁdence interval; AA, African-American; MSM, men who have se
a Sex, age, year of HIV diagnosis were not included in ﬁnal multiple logistic regressi
b Reference category.
c Log10-transformed viral load was entered into the regression model as a continuou
d Describes the change in the odds of having a resistance mutation per every changhad L21W, two (14%) had M184 v/i, one had G190 (7%), one had
L74 V (7%), one had K19w (7%), and one had L76 v (7%).
Viral load was also associated with antiretroviral resistance
mutations (p < 0.001). Thus, three of ﬁve individuals (60%) with a
viral load between 2.3 and 3 log10 copies/ml had antiretroviral
resistance mutations, whereas only 20 of 81 (25%) with a viral load
of 3 to 5 log10 copies/ml and 0 of 47 with a viral load of 5 log10
copies/ml had resistance mutations.
In the multiple logistic regression analysis, log10-transformed
HIV viral load was found to be strongly associated with the
presence of resistance mutations (OR 0.04, 95% CI 0.01–0.14;
p < 0.001; Table 3). No other associations were found in this initial
model. Due to signiﬁcant correlation between CD4+ count and viral
load (Spearman’s rho = 0.52; p < 0.001), a second model without
viral load was used to describe the association between CD4+
count and resistance mutations. In this model, there was
signiﬁcant association between having a CD4+ >350 cell/ml and
the presence of resistance mutations (OR 6.7, 95% CI 1.8–24.6;
p = 0.004). No other associations were found in the second model.
To determine if there was any clustering of drug-resistant virus
sequences in our cohort, all 133 RT and PR sequences and the
reference sequence K03455 were submitted for phylogenetic
analysis. The tree that was constructed revealed one small related
cluster of sequences representing approximately one-quarter of
those sequences harboring TDRM (Figure 1). These TDRM
sequences identiﬁed within the circle contained only the L90 M
mutation.
4. Discussion
Since the early 1990s, public health efforts have focused on
identifying HIV infection at an early stage. Our data, similar to a
larger dataset recently published by Althoff et al.,2 show that most
patients continue to ﬁrst present for HIV care with a CD4+ count
below 350 cells/mm3. Only 20% of our patients had counts above
500 CD4+ cells/ml, while 46% had counts below 200 cells/ml and
51% had AIDS at the time of HIV diagnosis.
A recent study from Wheeler et al.7 reported a 14.6% prevalence
of TDRM in the USA, which is higher than recent estimates
from similarly designed datasets in Canada (8.1%) and Europeic regression analysis
OR (CI 95%) p-Value, adjusted analysis
Unadjusted Adjusteda
Ref.b
0.8 (0.3–2.3)
Ref.b
0.8 (0.3–2.6) 0.8 (0.2–4.4) 0.823
0.6 (0.1–2.1) 0.3 (0.1–2.6) 0.300
0.6 (0.2–2.2) 0.9 (0.1–5.6) 0.921
Ref.b
0.9 (0.3–3.1)
0.8 (0.1–8.1)
Ref.b
2.2 (0.9–5.8) 3.3 (0.8–13.7) 0.098
2.5 (0.2–27) 1.2 (0.1–75.4) 0.927
Ref.b
0.9 (0.3–3.1)
1.1 (0.4–3.1)
Ref.b
2.1 (0.7–11.8) 3.5 (08–15.7) 0.100
6.5 (1.9–21.6) 6.7 (1.8–24.6) 0.004
0.05 (0.02–0.17) 0.04 (0.01–0.14)d <0.001
x with men; IVDU, intravenous drug user.
on model.
s variable.
e in one unit of log10-transformed HIV viral load.
Figure 1. Phylogenetic analysis of the reverse transcriptase (RT) and protease (PR)
regions of HIV-1 sequences. All patient sequences were analyzed using neighbor-
joining (K-2-P) with 100 bootstrap replicates. Sequences with surveillance drug
resistance mutations are shown as red circles.
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inclusion of geographic areas in the current analysis that were not
included in previous surveillance reports.10,18 Hence, applying
national data to a particular region could overestimate or
underestimate the problem of TDRM. In our study the rate of
transmitted drug resistance was 17%, greater than that reported in
national datasets.7,18 Although this is almost twice the 8.7% rate
reported in Detroit in 2001,10 this estimation was obtained from
only 46 patients and combined data from the Detroit/Grand Rapids
area. Our data suggest that HIV-1 drug resistance transmission
rates in Detroit are similar to those that have been observed in
large metropolitan areas of the USA, such as San Francisco and
Washington DC.19,20
In this study, we did not observe any subjects with three
thymidine analogue mutations (TAMS). However, 3% of subjects
had two TAMS and 2% had virus with M184 V. We also observed an
increased frequency of L90 M mutation: 4.5% compared to the 0.1%
reported by Bennett et al.12 This high rate of L90 M mutation may
possibly reﬂect high level usage of ritonavir-boosted protease
inhibitor in our community21,22 or the persistence of mutations
selected by past saquinavir and nelﬁnavir usage.
While it is possible that presentation to our facility by
individuals seeking care may have been biased as a result of
multiple transmission clusters, the results of the phylogenetic
analysis revealed little clustering of RT and PR sequences that
contained relevant drug resistance mutations within this cohort.
On the other hand, the small cluster identiﬁed may explain the
overall increase in L90 M observed. This does not necessarily
reduce the signiﬁcance of the presence of the L90 M mutation in
this population, as the dynamics of HIV transmission may involve
high and low periods of activity and clusters of new infection, as
opposed to steady-state dynamics.23 Thus while the single cluster
might inﬂate resistance estimates, such clusters may legitimately
reﬂect the epidemiology of transmission.
In this study a high proportion of RT and PI mutations were
more often observed among those with higher CD4+ cell counts.
While the signiﬁcance of this ﬁnding is uncertain, it suggests that
persons with more recently acquired infection are at increased risk
of acquisition of resistant HIV. It is also possible that some
individuals with lower CD4+ counts and longer standing infection
may have reverted to a predominance of wild-type virus.24–26 In
support of this is the observation that higher viral loads were
inversely associated with the detection of antiretroviral-associated
mutations (although ﬁtness-impairing mutations, themselves,may result in lower viral loads). Deep sequencing methodologies
would be able to address this question more fully as suggested by
Johnson et al., who reported a two-fold increase in the detection of
resistance mutations with ultrasensitive methods in newly
diagnosed HIV persons.27
There are some limitations to this study. While individuals
reported no prior HIV diagnosis and no prior antiretroviral
exposure, it is possible that a few individuals may have been
diagnosed and treated elsewhere. Moreover, not all newly
diagnosed individuals were included in the analysis given the
requirement for genotypic testing. Additionally, this was a single-
center study and might not totally reﬂect the complex epidemiol-
ogy of HIV infection in the Detroit area. The large number of
individuals in our study who reported heterosexual behavior/
acquisition may reﬂect an overestimation due to incomplete
investigation; for example, in 18% of newly diagnosed Detroit cases
risk has been as yet undetermined. However, Michigan Depart-
ment of Community Health surveillance data indicate that at the
time of diagnosis 89% of Detroit residents were black, 28% were
female, and 42% were classiﬁed as MSM.4 Therefore, although this
was a single site study, the data reported in this study are likely to
be broadly representative of the HIV population living in the
Detroit area.
In summary, as the HIV epidemiology evolves, it is important
not only to understand the epidemic nationally, but also to have a
better understanding of the local/regional epidemic, which has its
own distinctive characteristics. Our data show that late diagnosis
of HIV and transmitted antiretroviral resistance are relatively
common in Detroit. While most newly diagnosed persons were
candidates for ART on presentation, the high prevalence of
transmitted drug resistance mutations has potential implications
in the selection of ﬁrst-line highly active antiretroviral therapy
(HAART). Even in the absence of NNRTI resistance, background
NRTI resistance may impair responses to NNRTI- or integrase-
containing regimens, as evidenced in SWITCHMRK for raltegravir-
based regimens.28,29 Therefore, it is important to consider local
patterns of resistance in the selection of initial ART. This is
particularly important in those situations when therapy may be
started empirically prior to the availability of results from
susceptibility testing.
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